Technical Analysis for WAVE - Waverly Pharma Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | 29 days ago |
| 20 DMA Resistance | 30 days ago |
| 10 DMA Resistance | 30 days ago |
| Rose Above 20 DMA | 30 days ago |
| Rose Above 10 DMA | 30 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-11-25
Waverley Pharma Inc is a Canada-based company engaged in Biotechnology & Medical Research sector.The Company is focused on developing and commercializing Safe and Effective Small Molecules for Treatment of Cancer. Waverley Pharma is working in collaboration with a Indian conglomerate based in Mumbai to develop products for the treatment of cancer. Two of the lead products under developments are: WAV-101: WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications; WAV-102 is also an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. The Company has signed an agreement with Omgene Life Sciences for the development of another generic anti-cancer product WAV-103.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Occupational Safety And Health Medicine Pharma Labor Drug Biotechnology Science Cancer Life Sciences Therapy Collaboration Oncology Drug Development Lung Cancer Treatment Of Cancer Chemotherapy Non Small Cell Lung Cancer Multiple Myeloma Treatment Of Non Small Cell Lung Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Occupational Safety And Health Medicine Pharma Labor Drug Biotechnology Science Cancer Life Sciences Therapy Collaboration Oncology Drug Development Lung Cancer Treatment Of Cancer Chemotherapy Non Small Cell Lung Cancer Multiple Myeloma Treatment Of Non Small Cell Lung Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.14 |
| 52 Week Low | 0.01 |
| Average Volume | 21,268 |
| 200-Day Moving Average | 0.049 |
| 50-Day Moving Average | 0.021 |
| 20-Day Moving Average | 0.017 |
| 10-Day Moving Average | 0.018 |
| Average True Range | 0.005 |
| RSI (14) | 45.05 |
| ADX | 6.4 |
| +DI | 26.667 |
| -DI | 28.182 |
| Chandelier Exit (Long, 3 ATRs) | 0.021 |
| Chandelier Exit (Short, 3 ATRs) | 0.024 |
| Upper Bollinger Bands | 0.023 |
| Lower Bollinger Band | 0.010 |
| Percent B (%b) | 0.36 |
| BandWidth | 77.381 |
| MACD Line | -0.002 |
| MACD Signal Line | -0.002 |
| MACD Histogram | -0.0002 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.015 | ||||
| Resistance 3 (R3) | 0.015 | 0.015 | 0.015 | ||
| Resistance 2 (R2) | 0.015 | 0.015 | 0.015 | 0.015 | |
| Resistance 1 (R1) | 0.015 | 0.015 | 0.015 | 0.015 | 0.015 |
| Pivot Point | 0.015 | 0.015 | 0.015 | 0.015 | 0.015 |
| Support 1 (S1) | 0.015 | 0.015 | 0.015 | 0.015 | 0.015 |
| Support 2 (S2) | 0.015 | 0.015 | 0.015 | 0.015 | |
| Support 3 (S3) | 0.015 | 0.015 | 0.015 | ||
| Support 4 (S4) | 0.015 |
